CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies

• CARISMA receives full rights to use the CAP® Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications
• CEVEC’s unique CAP® cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors
• The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors
  

Cologne, Germany and Philadelphia, PA, February 2, 2021